Showing 1189 results
-
Press Release /Collaboration with Aduro is focused on discovery and development of next generation cancer immunotherapies targeting the STING signaling pathway Addition of STING agonists further enhances…
-
Press Release /After two full years of therapy with Cosentyx 300 mg, almost 9 out of 10 psoriasis patients sustained their PASI 75 response[1] New data at AAD shows 7 out of 10 psoriasis patients, who…
-
Press Release /CLEAR study at AAD showed over 21% more psoriasis patients achieved clear to almost clear skin (PASI 90) with Cosentyx(TM) compared to Stelara® at Week 16[1] Cosentyx showed greater improvements…
-
Press Release /Jakavi® (ruxolitinib) approved by the European Commission for adult patients with polycythemia vera (PV) resistant to or intolerant of hydroxyurea PV is a rare blood cancer associated with…
-
Press Release /Detailed results from the CLEAR study will be revealed showing Cosentyx superiority to Stelara® in clearing skin (PASI 90 and PASI 100)[1] New data from the long-term Phase III program to…
-
Press Release /Sandoz is the first company to receive approval of a biosimilar in the US through the new FDA biosimilars pathway established under BPCIA Zarxio is approved for all indications included in the…
-
Press Release /Completes transactions with GSK including: acquisition of GSK oncology portfolio, creation of Consumer Healthcare joint venture, and sale of non-influenza Vaccines business Sharpens company focus…
-
Press Release /Mit GSK abgeschlossene Transaktionen: Übernahme des Onkologie-Portfolios von GSK, Schaffung eines Joint Venture für Consumer Healthcare und Veräusserung des Bereichs Vaccines (ohne Grippeimpfstoffe…
-
Press Release /Conclusion des transactions avec GSK incluant : l'acquisition du portefeuille oncologie de GSK, la création d'une coentreprise de Consumer Healthcare et la cession de l'activité vaccins (hors…
-
Press Release /Phase II study met primary endpoint, demonstrating promising visual acuity gains in patients with neovascular (wet) age-related macular degeneration Data shows the potential for less…